Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2017

Open Access 01-03-2017 | Review

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Authors: Daniel A. Grabell, Adelaide A. Hebert

Published in: Dermatology and Therapy | Issue 1/2017

Login to get access

Abstract

Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient’s quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.
Literature
1.
Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51(2):241–8.PubMedCrossRef
2.
Moraites E, Vaughn OA, Hill S. Incidence and prevalence of hyperhidrosis. Dermatol Clin. 2014;32(4):457–65.PubMedCrossRef
3.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10–3.PubMedCrossRef
4.
Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS ONE. 2016;11(4):e0153719.PubMedPubMedCentralCrossRef
5.
Lai FC, Tu YR, Li YP, Li X, Lin M, Chen JF, et al. Nation wide epidemiological survey of primary palmar hyperhidrosis in the People’s Republic of China. Clin Auton Res. 2015;25(2):105–8.PubMedCrossRef
6.
7.
8.
Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg. 2002;35(2):382–6.PubMedCrossRef
9.
Higashimoto I, Yoshiura K, Hirakawa N, Higashimoto K, Soejima H, Totoki T, et al. Primary palmar hyperhidrosis locus maps to 14q11.2-q13. Am J Med Genet A. 2006;140(6):567–72.PubMedCrossRef
10.
Shih CJ, Wu JJ, Lin MT. Autonomic dysfunction in palmar hyperhidrosis. J Auton Nerv Syst. 1983;8(1):33–43.PubMedCrossRef
11.
Birner P, Heinzl H, Schindl M, Pumprla J, Schnider P. Cardiac autonomic function in patients suffering from primary focal hyperhidrosis. Eur Neurol. 2000;44(2):112–6.PubMedCrossRef
12.
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.PubMedCrossRef
13.
Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf. 2008;31(2):109–26.PubMedCrossRef
14.
Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8(8):693–8.PubMedCrossRef
15.
Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci. 2000;37(1):25–31.PubMed
16.
Glaser DA, Coleman WP 3rd, Fan LK, Kaminer MS, Kilmer SL, Nossa R, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012;38(2):185–91.PubMedCrossRef
17.
Shelley WB, Hurley HJ Jr. Studies on topical antiperspirant control of axillary hyperhidrosis. Acta Derm Venereol. 1975;55(4):241–60.PubMed
18.
Brandrup F, Larsen PO. Axillary hyperhidrosis: local treatment with aluminum chloride hexahydrate 25% in absolute ethanol. Acta Derm Venereol. 1978;58(5):461–5.PubMed
19.
Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol. 1990;29(5):368–70.PubMedCrossRef
20.
21.
Holzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol. 1984;110(4):399–403.PubMedCrossRef
22.
Scholes KT, Crow KD, Ellis JP, Harman RR, Saihan EM. Axillary hyperhidrosis treated with alcoholic solution of aluminium chloride hexahydrate. Br Med J. 1978;2(6130):84–5.PubMedPubMedCentralCrossRef
23.
24.
Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115–9.PubMed
25.
26.
27.
Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol. 2007;157(1):118–21.PubMedCrossRef
28.
Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol. 2008;158(5):1094–7.PubMedCrossRef
29.
Hyun MY, Son IP, Lee Y, Choi HG, Park KY, Li K, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–82.PubMedCrossRef
30.
Mackenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol. 2013;169(2):483–4.PubMedCrossRef
31.
Kavanagh GM, Burns C, Aldridge RD. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. Br J Dermatol. 2006;155(2):487.PubMedCrossRef
32.
Songur A, Ozen OA, Sarsilmaz M. The toxic effects of formaldehyde on the nervous system. Rev Environ Contam Toxicol. 2010;203:105–18.PubMed
33.
Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol. 2012;66(3):387–92.PubMedCrossRef
34.
Paller AS, Shah PR, Silverio AM, Wagner A, Chamlin SL, Mancini AJ. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol. 2012;67(5):918–23.PubMedCrossRef
35.
Wolosker N, de Campos JR, Kauffman P, Puech-Leao P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696–700.PubMedCrossRef
36.
Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, Zagnoli A, Chassain-Le Lay M, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163–8.PubMedCrossRef
37.
Costa Ada S Jr, Leao LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, et al. Randomized trial—oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. Clinics (Sao Paulo). 2014;69(2):101–5.PubMedCrossRef
38.
Sergi R, Massone A, Moretto S, Oggerino C, Bertolotto F, Losio L, et al. Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients. Spinal Cord. 2008;46(8):571–3.PubMedCrossRef
39.
40.
Muller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, et al. Efficacy and safety of methantheline bromide (Vagantin((R))) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2013;27(10):1278–84.PubMed
41.
Torch EM. Remission of facial and scalp hyperhidrosis with clonidine hydrochloride and topical aluminum chloride. S Med J. 2000;93(1):68–9.CrossRef
42.
Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–9.PubMedCrossRef
43.
Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013;67:115–28.PubMedCrossRef
44.
Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107(Pt A):77–84.
45.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596–9.PubMedPubMedCentralCrossRef
46.
Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg. 2002;28(6):480–3.PubMed
47.
Naumann M, Lowe NJ, Kumar CR, Hamm H, Hyperhidrosis Clinical Investigators G. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139(6):731–6.PubMedCrossRef
48.
Lecouflet M, Leux C, Fenot M, Celerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: a study of 28 patients. J Am Acad Dermatol. 2014;70(6):1083–7.PubMedCrossRef
49.
Talarico-Filho S, Mendonca DONM, Sperandeo DEMF, C DESP. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S44–50.
50.
Heckmann M, Plewig G, Hyperhidrosis Study G. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol. 2005;141(10):1255–9.PubMedCrossRef
51.
Rystedt A, Swartling C, Farnstrand C, Naver H. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol. 2008;88(5):458–61.PubMedCrossRef
52.
Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology. 2001;57(11):2095–9.PubMedCrossRef
53.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of dysport vs. botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041–5.
54.
Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 1997;136(4):548–52.PubMedCrossRef
55.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2002;28(9):822–7.PubMed
56.
D’Epiro S, Macaluso L, Salvi M, Luci C, Mattozzi C, Marzocca F, et al. Safety and prolonged efficacy of botulin toxin A in primary hyperhidrosis. Clin Ter. 2014;165(6):e395–400.PubMed
57.
Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):505–15.PubMedCrossRef
58.
Kuwahara RT, Skinner RB. Emla versus ice as a topical anesthetic. Dermatol Surg. 2001;27(5):495–6.PubMed
59.
Dixit S, Lowe P, Fischer G, Lim A. Ice anaesthesia in procedural dermatology. Australas J Dermatol. 2013;54(4):273–6.PubMedCrossRef
60.
Patel R, Halem M, Zaiac M. The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. J Drugs Dermatol. 2009;8(10):948–51.PubMed
61.
Sharma P, Czyz CN, Wulc AE. Investigating the efficacy of vibration anesthesia to reduce pain from cosmetic botulinum toxin injections. Aesthet Surg J. 2011;31(8):966–71.PubMedCrossRef
62.
O’Riordan JM, Fitzgerald E, Gowing C, O’Grady H, Feeley TM, Tierney S. Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis. Br J Surg. 2006;93(6):713–4.PubMedCrossRef
63.
Elibol O, Ozkan B, Hekimhan PK, Caglar Y. Efficacy of skin cooling and EMLA cream application for pain relief of periocular botulinum toxin injection. Ophthal Plast Reconstr Surg. 2007;23(2):130–3.PubMedCrossRef
64.
Gulec AT. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study. J Eur Acad Dermatol Venereol. 2012;26(3):314–8.PubMedCrossRef
65.
Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol. 2007;156(5):986–9.PubMedCrossRef
66.
Solomon P. Modified Bier block anesthetic technique is safe for office use for botulinum a toxin treatment of palmar and plantar hyperhidrosis. Dermatol Online J. 2007;13(3):6.PubMed
67.
Ponce-Olivera RM, Tirado-Sanchez A, Arellano-Mendoza MI, Leon-Dorantes G, Kassian-Rank S. Palmar hyperhidrosis. Safety efficacy of two anaesthetic techniques for botulinum toxin therapy. Dermatol Online J. 2006;12(2):9.PubMed
68.
de Almeida AR, Kadunc BV, de Oliveira EM. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg. 2001;27(1):34–6.PubMedCrossRef
69.
Fujita M, Mann T, Mann O, Berg D. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis. J Am Acad Dermatol. 2001;45(4):587–9.PubMedCrossRef
70.
Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Dermatol. 1968;98(5):505–7.PubMedCrossRef
71.
72.
Thomas L, Fatah S, Carmichael AJ. Tap water iontophoresis may be ineffective for axillary hyperhidrosis. Clin Exp Dermatol. 2015;40(3):337–8.PubMedCrossRef
73.
Hill AC, Baker GF, Jansen GT. Mechanism of action of iontophoresis in the treatment of palmar hyperhidrosis. Cutis. 1981;28(1):69–70, 2.
74.
Wang L, Hilliges M, Gajecki M, Marcusson JA, Johansson O. No change in skin innervation in patients with palmar hyperhidrosis treated with tap-water iontophoresis. Br J Dermatol. 1994;131(5):742–3.PubMedCrossRef
75.
76.
Karakoc Y, Aydemir EH, Kalkan MT, Unal G. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol. 2002;41(9):602–5.PubMedCrossRef
77.
Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol. 1987;123(7):893–6.PubMedCrossRef
78.
Chia HY, Tan AS, Chong WS, Tey HL. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2012;26(9):1167–70.PubMedCrossRef
79.
80.
Abell E, Morgan K. The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis. Br J Dermatol. 1974;91(1):87–91.PubMedCrossRef
81.
82.
Lupin M, Hong HC, O’Shaughnessy KF. Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatol Surg. 2014;40(7):805–7.PubMed
83.
Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6(3):243–62.PubMedCrossRef
84.
Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78(6):696–702.PubMedCrossRef
85.
Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study G. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140–5.
86.
Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015;34(1):37–43.PubMedCrossRef
87.
Schick CH, Grallath T, Schick KS, Hashmonai M. Radiofrequency thermotherapy for treating axillary hyperhidrosis. Dermatol Surg. 2016;42(5):624–30.PubMedCrossRef
88.
Kim M, Shin JY, Lee J, Kim JY, Oh SH. Efficacy of fractional microneedle radiofrequency device in the treatment of primary axillary hyperhidrosis: a pilot study. Dermatology. 2013;227(3):243–9.PubMedCrossRef
89.
Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–84.PubMedCrossRef
90.
Abtahi-Naeini B, Naeini FF, Saffaei A, Behfar S, Pourazizi M, Mirmohammadkhani M, et al. Treatment of primary axillary hyperhidrosis by fractional microneedle radiofrequency: is it still effective after long-term follow-up? Indian J Dermatol. 2016;61(2):234.PubMedPubMedCentral
91.
Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol. 2012;11(1):59–63.PubMed
92.
Bechara FG, Georgas D, Sand M, Stucker M, Othlinghaus N, Altmeyer P, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg. 2012;38(5):736–40.PubMedCrossRef
93.
Leclere FM, Moreno-Moraga J, Alcolea JM, Vogt PM, Royo J, Cornejo P, et al. Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial. Lasers Surg Med. 2015;47(2):173–9.PubMedCrossRef
94.
Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol. 2014;7(4):14–21.PubMedPubMedCentral
95.
Commons GW, Lim AF. Treatment of axillary hyperhidrosis/bromidrosis using VASER ultrasound. Aesthetic Plast Surg. 2009;33(3):312–23.PubMedCrossRef
96.
97.
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.PubMed
Metadata
Title
Current and Emerging Medical Therapies for Primary Hyperhidrosis
Authors
Daniel A. Grabell
Adelaide A. Hebert
Publication date
01-03-2017
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2017
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0148-z

Other articles of this Issue 1/2017

Dermatology and Therapy 1/2017 Go to the issue

Case Report

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up

Case Report

A Report of Two Cases of Solid Facial Edema in Acne

Original Research

Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients

Review

Systemic Treatment of Adult Atopic Dermatitis: A Review

Original Research

Fixed-Combination Gels of Adapalene and Benzoyl Peroxide Provide Optimal Percutaneous Absorption Compared to Monad Formulations of These Compounds: Results from Two In Vitro Studies

Review

Vegas (Verruciform Genital-Associated) Xanthoma: A Comprehensive Literature Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits